The collaboration will use results-based financing to achieve its goals.
Organon and CAF, Development Bank of Latin America, announced that they are collaborating to increase sustainable financing in women’s health. The two organizations will design and implement sustainable programs for women in Latin America and the Caribbean. These programs will improve equity, health, and autonomy for the women involved.
In a press release, the two organizations announced that they had signed a memorandum of understanding with the United Nations Sustainable Development Goals.
These programs will aim to provide sustainable financing to women in the targeted areas.
“At Organon, we believe that results-based financing can drive collective action to progressing women’s health goals,” Kevin Ali, Organon CEO, said in the press release. “We are proud of our first-of-its-kind collaboration with CAF, built specifically to positively affect the health of women–and ultimately a country’s economy and development.”
Organon describes itself as a global healthcare company focused on improving women’s health.
“This agreement with Organon will help us to join forces in order to break with the structural barriers that keep limiting the access of women to health, financial and non-financial services,” Sergio Diaz-Granados, Executive President of CAF said in the press release.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.